NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Miranda Adrian reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. reported an equity compensation grant to executive Adrian Miranda, its CMO and SVP Science & Tech. Miranda received 133,341 RSUs, each representing one share of common stock, as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs vest in three equal annual installments over three years, and Miranda now directly holds 133,341 RSUs tied to common shares.
Keyser Jane Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. director Jane Elizabeth Keyser reported an award of 26,073 shares of Common Stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for her services as an independent director. Following this grant, her direct holdings total 72,408 shares of Neuraxis common stock.
Henrichs Timothy Robert reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported an equity compensation grant to its Chief Financial Officer, Timothy Robert Henrichs. He received 141,479 RSUs, representing the right to receive an equal number of shares of common stock. The award was valued at $6.28 per unit for reporting purposes and was granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over three years, and the filing shows Henrichs holding 141,479 shares/units directly following this award.
Ferge Kristin A reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, INC director Kristin A. Ferge received a grant of 31,134 shares of common stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for services as an independent director, bringing her directly held common stock position to 67,072 shares after the award.
Carrico Thomas Joeseph reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. reported that officer Thomas Joeseph Carrico received a grant of 135,906 RSUs of common stock as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs, valued at $6.28 per unit, vest in three equal annual installments over a three-year period, and Carrico now directly holds 135,906 RSUs.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported that Chief Executive Officer and director Brian Allen Carrico received a grant of 193,329 restricted stock units (RSUs) as equity compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Following this award, his directly held RSU-based common stock position reported in this filing is 193,329 shares.
Neuraxis, INC director Aharon Gil reported three acquisitions of Common Stock of NRXS. On 2026-08-13, he received 43,930 shares at $6.28 per share as compensation for serving as an independent director. On 2026-07-29, he and Rosalind Master Fund L.P. received 2,226 and 40,068 shares, respectively, as stock dividends on their Series B Preferred Stock, based on accrued 8.5% cumulative dividends divided by $2.38. The 40,068-share position is reported as indirect ownership through Rosalind Advisors, Inc., with beneficial ownership disclaimed except for each party’s pecuniary interest, and total indirect holdings after these transactions are 548,123 shares.
NeurAxis, Inc. reported rapid top-line growth but continued losses for the quarter and six months ended June 30, 2026. Net sales rose to $1.93 million for the quarter and $3.54 million year-to-date, driven by broader insurance coverage following IB-Stim’s Category I CPT code and higher average selling prices. Gross margin remained high at 85.9–86.1%, yielding gross profit of $3.05 million for the six months.
Operating loss was $3.87 million and net loss $3.85 million year-to-date, slightly better than 2025 but still significant. Cash and cash equivalents increased to $8.32 million, largely from equity offerings and warrant exercises, supporting working capital of $6.32 million. Stockholders’ equity improved to $6.74 million as of June 30, 2026.
The company emphasizes going-concern risks, citing a history of operating losses and dependence on continued sales growth and external financing. It highlights a focused neuromodulation portfolio (IB-Stim and RED), expanding clinical studies, and ongoing efforts to secure broader payor coverage as key drivers of future performance.
Neuraxis, Inc. is registering for resale up to 1,923,194 shares of common stock held by existing security holders. This is a secondary offering: only the selling stockholders will receive proceeds from any sale, while Neuraxis will not receive any cash from these transactions.
The registered shares consist of 849,212 issued shares, 923,776 shares underlying RSUs, and 150,206 shares issued to directors. As of July 22, 2026, 12,477,309 shares of common stock were outstanding. The selling stockholders may sell shares over time through various methods, including market and negotiated transactions, and may be deemed underwriters depending on how they sell.
Neuraxis is a growth-stage medical technology company focused on neuromodulation therapies for gastrointestinal disorders, led by its proprietary IB-Stim PENFS device for pediatric and adult functional abdominal pain and its RED device for rectal neuromuscular evaluation. The company is listed on the NYSE American under the symbol NRXS, with a closing share price of $6.59 on August 3, 2026, and qualifies as an emerging growth company, with extensive risk factors incorporated by reference.